Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 15, 2003 Carla Pasternak	Cooper Eyes Big Gains The stock of rapidly growing contact lens maker Cooper is worth a look.
The Motley Fool June 7, 2006 Stephen D. Simpson	Cooper's Bleary Performance Missteps in strategy and operations for the contact lens company are coming home to roost. As is almost always the case with turnarounds, this is an idea with above-average risk, so don't make the mistake of underestimating the odds that things could get even worse.
The Motley Fool June 7, 2007 Billy Fisher	Envisioning a Clear Future at Cooper The contact lens and eye care-product company posts a second-quarter loss upon restructuring, but revenues continue to grow. The outlook is fairly positive for Cooper shareholders for the remainder of the year.
The Motley Fool March 7, 2007 Steven Mallas	1-800 CONTACTS: I Just Don't See It This lens maker is still one investors should avoid.
The Motley Fool September 10, 2007 Lawrence A. Rothman	Cooper Needs a Clearer Vision Earnings reports from vision-correction specialist Cooper show that revenue did rise, but gross margins decreased, and management lowered guidance significantly.
The Motley Fool April 19, 2005 Stephen D. Simpson	Do The Eyes Have It for Bausch & Lomb? New product launches and extensions coupled with improving margins should boost results. Investors, take note.
The Motley Fool August 7, 2006 Stephen D. Simpson	Advanced Medical Optics Still a Little Bloodshot This eye-care stock has done relatively well despite some ongoing sales issues.
The Motley Fool December 17, 2007 Anders Bylund	3 Stocks That Missed the Mark These companies overpromised and underdelivered: Cooper Companies... FreeSeas... CDC Corp...
The Motley Fool April 11, 2006 Rick Aristotle Munarriz	Bausch & Lomb Sees Eye to Ay The contact lens specialist gets tripped up over its potentially infected ReNu brand. Bausch & Lomb's stock took a 9% hit in after-hours trading on the news.
The Motley Fool March 5, 2007 Rich Smith	Foolish Forecast: Focus on 1-800 Contacts The contact lens purveyor reports fourth-quarter and full-year 2006 earnings shortly. Investors, here is what you can expect to see.
The Motley Fool May 31, 2007 Billy Fisher	Not Seeing 20/20 at Advanced Medical Optics The company recalls a contact lens solution that might be linked to a rare infection. Investors, take note.
The Motley Fool January 12, 2006 Stephen D. Simpson	The Guidant Auction Continues Johnson & Johnson hopes to save the deal with a last-minute raise of its offer. Although Boston Scientific's offer is $4 per share higher, that doesn't necessarily make it the best value. Investors, take note.
The Motley Fool April 13, 2004 Alyce Lomax	J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter.
The Motley Fool November 2, 2005 Stephen D. Simpson	AMO Focuses on the Giants Advanced Medical Optics sets its sights on the big players in eye care. Will David be able to take on the Goliaths? Investors, take note.
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward.
The Motley Fool October 7, 2010 Anand Chokkavelu	How Johnson & Johnson Really Makes Money Hint: It's not Tylenol.
Popular Mechanics March 2007 Alex Hutchinson	Forget Fisheye: A Photo Lens to Steer Robots A lens developed by South Korean researchers offers a wide-angle view without fisheye distortion, perfect for ceiling-mounted security cameras. Unlike images produced by fisheye lenses, straight lines appear straight.
The Motley Fool February 9, 2006 Stephen D. Simpson	Alcon Makes Traders Cry Disappointing guidance lets some of the air out of the valuation, but not enough.
BusinessWeek May 7, 2007 Gene G. Marcial	A Closer Look At Cooper Turnaround efforts and a search for a new chief at Cooper, whose coopervision arm makes contact lenses, have wall street in a wait-and-see stance.
BusinessWeek June 18, 2007 Arlene Weintraub	Johnson & Johnson's Next Baby? J&J could use an infusion of new drugs and devices from an acquisition such as Boston Scientific.
The Motley Fool May 20, 2011 Andrea Kalvesmaki	Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings.
The Motley Fool April 22, 2004 Brian Gorman	Bausch & Lomb Delivers The 150-year-old eye-care company's sales aren't sizzling, but its profitability is improving.
BusinessWeek January 30, 2006 Robert Barker	Guidant Or No, J&J Is A Buy To Wall Street, Johnson & Johnson has been sounding like Dumb & Dumber.
The Motley Fool January 13, 2006 Stephen D. Simpson	Once More With Guidant In the ongoing game of tit-for-tat, Boston Scientific ups its bid for Guidant. This battle will ultimately be decided by the 800-pound gorilla that is J&J. Investors, take note.
The Motley Fool May 4, 2007 Rich Duprey	Cooper Tire Headin' for the Highway This once-troubled tire maker is in full turnaround mode as revenues and profits soar.
The Motley Fool August 24, 2010 Brian Orelli	One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well.
The Motley Fool October 12, 2007 Ryan Fuhrmann	Dueling Fools: Johnson & Johnson Bull The bullish opinion on J&J is that the company is handling current difficulties well, and the low stock price makes for a bargain for investors.
The Motley Fool September 28, 2009 Brian Orelli	The Berkshire of Health Care Johnson & Johnson is becoming the Berkshire Hathaway of health care. In addition to its usual M.O. of bolt-on acquisitions, the health-care giant has recently taken some equity stakes in smaller drug companies.
The Motley Fool February 27, 2007 Rich Duprey	Foolish Forecast: An Inflated Cooper Tire The tire maker will report its fourth-quarter 2006 financial results shortly. Investors, here is what you can expect to see.
The Motley Fool April 16, 2008 Brian Orelli	Johnson & Johnson Chugs Along Strong growth, mostly from the weak dollar, fails to excite Johnson & Johnson's investors.
Fast Company March 2014 Adam Bluestein	Will Johnson & Johnson's New Innovation Centers Point The Way Toward Its Future? To visit the southeastern quadrant of Cambridge, Massachusetts, these days is to witness the rise of a new kind of city -- a glassy, gleaming pharmopolis dedicated to the discovery, development, and marketing of drugs.
The Motley Fool April 13, 2006 Doug Short	A Foolish Baby Shower: Johnson & Johnson If you're an advocate of these two rules -- "It's never too early to start investing" and "Invest in what you know" -- then here is an ideal pick for baby's first stock.
The Motley Fool January 20, 2004 Alyce Lomax	Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings.
The Motley Fool September 25, 2009 Brian Orelli	Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK.
The Motley Fool September 17, 2010 James Early	Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care.
The Motley Fool June 26, 2006 Stephen D. Simpson	J&J Makes an Expensive Deal J&J announced that it has reached an agreement with Pfizer to acquire the latter's consumer health-care business for $16.6 billion in cash. Consumer health is a fine business line, but is it worth this much money? Investors, take note.
The Motley Fool October 12, 2007 Ryan Fuhrmann	Dueling Fools: Johnson & Johnson Bull Rebuttal The bulls say that J&J's stock record speaks for itself, and that the current negative short-term news and flagging stock price have created a compelling risk/reward trade-off for investors.
The Motley Fool October 26, 2011	A Brief History of Johnson & Johnson's Returns J&J shares are much more reasonably valued today than they were ten years ago; shareholders are unlikely to experience the same going forward.
The Motley Fool January 28, 2011 Anand Chokkavelu	10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo.
The Motley Fool January 24, 2006 Stephen D. Simpson	Shake a Leg, J&J! J&J isn't a perfect story, but investors who buy today and hold for a while will be happy they did.
BusinessWeek October 7, 2010 Olga Kharif	Eyeglass Innovator: Ronald Blum Optometrist Ronald Blum says his electronic eyeglasses improve on bifocals and progressive lenses, which cause nausea and headaches for some wearers.
The Motley Fool November 26, 2007 Brian Orelli	Johnson & Johnson Reorganizes -- Who Wins? Johnson & Johnson announces the second phase of its reorganization plan. While it may take years to see whether the measures will help J&J, some other companies could benefit far more quickly.
The Motley Fool August 6, 2011 Seth Jayson	Why The Cooper Companies May Be About to Take Off Is the current inventory situation at The Cooper Companies out of line?
The Motley Fool March 24, 2011 Anand Chokkavelu	Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund."
The Motley Fool July 5, 2005 Brian Gorman	Bausch & Lomb Eyes China The firm's latest purchase will add geographic diversity to its pharmaceutical business. Investors, take note.
Chemistry World June 10, 2012 Yuandi Li	Polymer gel provides focus An injectable nanocomposite gel for replacing the eye lens could eliminate the need for complicated cataract surgery, say Japanese and Danish researchers.
PC Magazine September 28, 2005 David Murphy	Eyeballing Your Camera A Liquid lens for cameras is currently in development and would allow quicker and more precise focusing and optical zooming.
The Motley Fool October 19, 2005 Stephen D. Simpson	Honeywell May Be on Autopilot Can this huge conglomerate stay ahead of maturing markets? The company is on track to match its long-term record of mid-single-digit growth in annual structural free cash flow, offering no compelling reason to purchase shares today.
The Motley Fool May 2, 2011 Anupama Pattanaik	J&J Attempts to Create Major "Synthes"-is Johnson & Johnson will acquire the medical device maker for $21.3 billion.
The Motley Fool July 28, 2011 Melly Alazraki	J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet.